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Safety of a single low-dose 
of primaquine in addition to standard 
artemether-lumefantrine regimen for treatment 
of acute uncomplicated Plasmodium falciparum 
malaria in Tanzania
Richard Mwaiswelo1, Billy E. Ngasala1*, Irina Jovel2, Roland Gosling3,4, Zul Premji5, Eugenie Poirot3,4, 
Bruno P. Mmbando6, Anders Björkman2 and Andreas Mårtensson7
Abstract 
Background: This study assessed the safety of the new World Health Organization (WHO) recommendation of 
adding a single low-dose of primaquine (PQ) to standard artemisinin-based combination therapy (ACT), regardless 
of individual glucose-6-phosphate dehydrogenase (G6PD) status, for treatment of acute uncomplicated Plasmodium 
falciparum malaria in Tanzania.
Methods: Men and non-pregnant, non-lactating women aged ≥1 year with uncomplicated P. falciparum malaria 
were enrolled and randomized to either standard artemether-lumefantrine (AL) regimen alone or with a 0.25 mg/kg 
single-dose of PQ. PQ was administered concomitantly with the first AL dose. All drug doses were supervised. Safety 
was evaluated between days 0 and 28. G6PD status was assessed using rapid test (CareStart™) and molecular geno-
typing. The primary endpoint was mean percentage relative reduction in haemoglobin (Hb) concentration (g/dL) 
between days 0 and 7 by genotypic G6PD status and treatment arm.
Results: Overall, 220 patients, 110 per treatment arm, were enrolled, of whom 33/217 (15.2 %) were phenotypically 
G6PD deficient, whereas 15/110 (13.6 %) were genotypically hemizygous males, 5/110 (4.5 %) homozygous females 
and 22/110 (20 %) heterozygous females. Compared to genotypically G6PD wild-type/normal [6.8, 95 % confidence 
interval (CI) 4.67–8.96], only heterozygous patients in AL arm had significant reduction in day-7 mean relative Hb 
concentration (14.3, 95 % CI 7.02-21.55, p=0.045), however, none fulfilled the pre-defined haemolytic threshold value 
of ≥25 % Hb reduction. After adjustment for baseline parasitaemia, Hb, age and sex the mean relative Hb reduction 
was not statistically significant in both heterozygous and hemizygous/homozygous patients in both arms. A major-
ity of the adverse events (AEs) were mild and unrelated to the study drugs. However, six (4.4 %) episodes, three per 
treatment arm, of acute haemolytic anaemia occurred between days 0 and 7. Three occurred in phenotypically G6PD 
deficient patients, two in AL and one in AL + PQ arm, but none in genotypically hemizygous/homozygous patients. 
All patients with acute haemolytic anaemia recovered without medical intervention.
Conclusion: The findings support that the WHO recommendation of adding a single low-dose of PQ to standard AL 
regimen is safe for the treatment of acute uncomplicated P. falciparum malaria regardless of G6PD status in Tanzania.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Background
Malaria prevalence is declining globally. The success is 
primarily accredited to the increased use of long-lasting 
insecticide treated bed-nets (LLIN) and artemisinin-
based combination therapy (ACT) [1, 2]. This decline 
has rejuvenated dreams to eliminate malaria. However, 
to achieve this ambitious goal, new tools and strategies 
are needed, but equally important is to optimize the use 
of already available tools, such as malaria transmission-
blocking drugs.
Primaquine (PQ) is an 8-aminoquinoline anti-malarial 
drug synthesized in 1945. It has been primarily used in 
combination with schizonticidal drugs to achieve radi-
cal Plasmodium vivax and P. ovale cure due to its effect 
on hypnozoites [3]. However, PQ also has an effect on 
mature P. falciparum gametocytes [4]. The main draw-
back of PQ use is dose-dependent acute haemolysis in 
glucose-6-phosphate dehydrogenase (G6PD) deficient 
individuals, a sex linked genetic disorder [5].
In 2012, the World Health Organization (WHO) 
issued a new recommendation to add a single low-dose 
of PQ (0.25  mg/kg) to standard ACT regimen regard-
less of G6PD status as a tool to interrupt transmission in 
low transmission settings and for containment in areas 
threatened by artemisinin resistance [6, 7]. However, the 
recommendation is based on low-quality evidence [6, 8, 
9], and the potential impact of adding this single low-
dose PQ to ACT on development of haemolysis follow-
ing treatment for P. falciparum malaria is incompletely 
understood. Therefore, the aim of this study was to 
provide safety data on the new WHO recommendation 
when used in treatment of acute uncomplicated P. falci-
parum malaria in Tanzania, especially in patients with 
confirmed G6PD deficiency.
Methods
Study area
The trial was conducted at Yombo dispensary, Bagamoyo 
district, Tanzania between July and November 2014. The 
dispensary is located approximately 20  km from Baga-
moyo town. It serves around 7000 people. The dispensary 
has laboratory capacity to carry out malaria microscopy 
and rapid diagnostic test. P. falciparum is the predomi-
nant malaria species and Anopheles gambiae sensu stricto 
the main vector [10, 11]. Artemether-lumefantrine (AL) 
is used as the first-line drug for uncomplicated malaria, 
and LLIN is the major vector control method. G6PD 
deficiency prevalence in the study area is estimated to be 
9 % male hemizygous and 1.8 % female homozygous [12].
Study design
This was a randomized, single-blinded clinical trial com-
paring safety and efficacy of AL versus a single low-dose 
PQ added to the standard AL treatment (AL + PQ). Clin-
ical and parasitological cure rates will be presented in a 
separate publication. Patients with microscopically con-
firmed P. falciparum mono-infection were enrolled in the 
study, randomized to either AL or AL + PQ treatment, 
admitted during the first 3 days and thereafter followed-
up until day-28 after treatment initiation.
Study population
Participants were recruited from patients presenting 
at the study site with suspected acute uncomplicated P. 
falciparum malaria regardless of G6PD status. Inclusion 
criteria were: age  ≥1  year, weight  ≥10  kg, microscopy 
determined P. falciparum mono-infection, any parasitae-
mia level and a body temperature ≥37.5 °C or history of 
fever in the last 24 h, ability to swallow oral medication, 
ability and willingness to comply with the study proto-
col and stipulated follow-up visits, and written informed 
consent (in case of children a proxy consent from a 
parent/guardian).
Exclusion criteria included evidence of severe malaria 
or danger signs, known allergies to study medications, 
reported anti-malarial intake within the past 2  weeks, 
haemoglobin (Hb) concentration less than 8  g/dL, his-
tory of blood transfusion within last 90 days, febrile con-
dition other than malaria, known underlying chronic or 
severe diseases, pregnancy and breastfeeding in the first 
6 months.
Randomization and blinding
Block randomization with four blocks, two per arm, was 
used for treatment assignment. The blocks were strati-
fied by sex [13]. The randomization was performed using 
the computer software Research Randomizer version 4 
(Wesleyan University, Connecticut, USA) [14]. Opaque 
envelopes containing the predetermined treatment codes 
were kept sequentially in a male and female strata. The 
envelopes were opened by a study nurse just prior to the 
administration of the first treatment dose. To achieve the 
single-blinding, the PQ dose was prepared in the absence 
of patients, mixed with a coloured glucose-based syrup 
Trial registration number NCT02090036
Keywords: Plasmodium falciparum malaria, Primaquine, Glucose-6-phosphate dehydrogenase, Anaemia
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and then administer. The coloured glucose-based syrup 
alone was administered with AL first dose to patients 
allocated AL alone.
Treatment
All patients were treated with a standard three-day 
course of AL (Coartem®, Novartis) according to Tanza-
nian national treatment guidelines for uncomplicated P. 
falciparum malaria [15]. For patients allocated AL + PQ 
treatment, a single 0.25  mg/kg PQ dose (Primaquine 
phosphate, Sanofi) was prepared as previously described 
[13], and administered concomitantly with the first AL 
dose. All treatment doses were directly observed. A 
fatty snack (biscuits) was administered prior to all six 
AL doses to optimize absorption [16], and the single PQ 
dose to minimize gastrointestinal side effects [13]. All 
drug doses were administered by a study nurse, and the 
participants were observed for 30  min after each drug 
dose. Treatment was readministered in cases of vomiting 
within this time period.
Patient withdrawals
Patients were withdrawn from the study in case of: 
vomiting the study drug over three times, withdrawal 
of consent, intake of any drug with anti-malarial prop-
erties outside the study protocol, or any protocol viola-
tion. Patients who missed a scheduled follow-up visit 
and would not be found despite efforts to trace them at 
their homes were considered lost to follow-up and con-
sequently withdrawn. Patients with repetitive vomiting 
of study drug were managed according to national guide-
lines and followed up until recovery.
Procedures
Clinical and laboratory assessments were performed on 
days 0, 1, 2, 3, 7, 10, 14, 21, 28, and on any day of recur-
rent illness. Every clinical assessment included history 
of clinical symptoms, possible adverse events, concomi-
tant drug consumption and clinical examination includ-
ing measurement of axillary temperature. All clinical and 
laboratory data were recorded in a case record form. The 
safety assessment was performed using the primaquine 
roll out monitoring pharmacovigilance tool (PROMPT) 
[17]. Adverse events (AE) and serious adverse event 
(SAE) were defined as previously defined [18].
At each visit, data on any post-treatment AE were col-
lected with the following information recorded: type of 
AE (rash, nausea, vomiting, anaemia, dark urine, other), 
date of onset, severity grade (mild, moderate, severe), any 
actions taken (prescribed drug, blood transfusion, other), 
its relatedness to PQ (definitely related, probably, possi-
bly, unlikely, not related), date resolved, outcome of AE, 
and any concomitant drug intake during the study.
All patients received an information card with instruc-
tions on how to identify signs and symptoms of com-
monly reported AEs including monitoring of urine 
colour. In addition, patients were given a clear container 
and asked to provide a urine sample on day 0 prior to first 
drug-dose and on days 1 and/or 2 or 3. The urine colour 
estimation of haemoglobinuria was gauged against the 
Hillmen colour chart with a colour score ranging from 1 
to 10 [19]. Staff assigning colours to urine were blinded 
to the treatment allocation. A colour score ≥5 was con-
sidered evidence of haemoglobinuria indicating acute 
haemolysis. Acute haemolysis was defined as fractional 
Hb fall ≥25  % from the pre-treatment value or macro-
scopic haemoglobinuria (Hillmen  ≥5) between the day 
of enrolment and day 7. Acute haemolytic anaemia was 
defined as any Hb drop to ≤7 g/dL, or ≥25 % from the 
pre-treatment value accompanied by a Hillmen urine col-
our score ≥5 between the day of enrolment and day 7.
Laboratory assessment involved collection of finger-
prick blood samples for Hb concentration, thick film for 
microscopy to assess presence and density of asexual par-
asitaemia and gametocytaemia, and thin film for species 
determination.
Hb concentration was measured using a portable spec-
trophotometer, HemoCue Hb 201  +  (HemoCue AB, 
Ängelholm Sweden), with a precision of ±0.3 g/dL. The 
HemoCue was calibrated every morning by using a con-
trol cuvette at 16.0 ± 0.3 g/dL according to manufactur-
er’s instruction.
The smears were stained using 10 % Giemsa and read 
by qualified microscopists. Asexual parasites on thick 
smears were counted against 200 white blood cells 
(WBC). This number was multiplied by 40, assum-
ing 8000 leukocytes per microlitre of blood, to gain an 
approximate parasite density. A blood slide was con-
sidered negative if no parasites were seen after examin-
ing 100 fields. Two, independent microscopists read all 
microscopy slides. In cases of discordance in the pres-
ence of parasitaemia, or in parasite density by more than 
25 %, a third independent reading was done. The majority 
result was taken as final in case of positive versus nega-
tive results and the geometric mean of the two closest 
parasite density estimates.
At enrolment, phenotypic G6PD screening and fil-
ter paper blood sampling for polymerase chain reaction 
(PCR)-based G6PD genotyping were also collected using 
capillary blood. The filter papers (3MM Whatman) were 
labeled, air-dried at room temperature for 3–4 h, packed 
in individual plastic bags, and then transported to Karo-
linska Institutet, Sweden, for molecular analysis.
G6PD phenotypic screening was performed at inclu-
sion using a rapid enzyme chromatographic test (Car-
eStart™, Access Bio, Inc. New Jersey, USA), (Cat. Ref. No. 
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G0221), following the manufacturer instructions. Test 
results were read visually after 10–15 min. A distinct pur-
ple colour in the result window was interpreted as nor-
mal G6PD activity, while no colour change or a very faint 
purple colour was interpreted as deficient G6PD activity. 
The quality of rapid test reading was controlled by two or 
more individuals reading the test. The test was repeated 
in case the research team is not satisfied with the test 
result.
G6PD genotyping was performed from dried blood 
spots on filter paper. Genomic DNA was extracted using 
10  % chelex [20], followed by DNA amplification using 
single-round PCR and restricted fragment length poly-
morphism (RFLP) digestion using restriction enzymes 
for the two most common polymorphisms associated 
with G6PD deficiency in Africa (i.e., G6PD A376G and 
G202A), as previously described [12]. The digested prod-
ucts were loaded on 3 % agarose gel containing GelRed™ 
(Biotium, Inc. Hayward, California, USA), separated 
by electrophoresis and visualized in a Gel Doc™ (Bio-
Rad, Hercules, California, USA) under ultraviolet light 
using Image Lab™ software (Bio-Rad, Hercules, Califor-
nia, USA). First, G6PD A376G analysis was performed. 
All samples with 376G mutation were then subjected to 
G6PD G202A analysis and the outcomes were classified 
as follows: for males A was defined as wild-type/normal 
and A- as hemizygous/deficient G6PD status, whereas for 
females A-A- was defined as homozygous/deficient, AA- 
and BA- as heterozygous/intermediate, and AA and BA 
as wild-type/normal G6PD status [12].
Study end‑points
The primary endpoint was mean relative reduction in Hb 
concentration (g/dL) between day 0 and 7. Secondary 
endpoints included: mean absolute reduction in Hb con-
centration between days 0 and 7; proportion of patients 
with a Hillmen urine colour score  ≥5 between days 1 
and 3; proportion of patients with adverse and serious 
adverse events; and the proportion of patients phenotypi-
cally/genotypically G6PD deficient.
Ethical considerations
The study was conducted in accordance with Good Clini-
cal Practices (GCP), the Declaration of Helsinki, and 
applicable regulatory requirements in Tanzania. The trial 
was approved by the Muhimbili University of Health 
and Allied Sciences and the National Institute for Medi-
cal Research ethics committees. Importation and use of 
PQ for research purposes were approved by the Tanza-
nia Food and Drug Authority. The Committee on Human 
Research at the University of California San Francisco 
approved the use of PROMPT to sites interested in its 
use. An independent data monitoring and safety board 
conducted an interim safety analysis during the trial. 
Written informed consent was obtained from all patients 
and a proxy consent from parents/guardians in patients 
aged  <18  years, prior to enrolment. The study is regis-
tered at clinicaltrials.gov (NCT02090036).
Statistical analysis
A total sample of 220, 110 per treatment arm, was calcu-
lated to be sufficient to detect within person reduction in 
Hb of ≥25 % between days 0 and 7 with 80 % power and 
a significance level of 0.05 (one-sided), assuming a mean 
Hb of 10 g/dL, a standard deviation of 2 and 25 % loss to 
follow-up. This sample size is also sufficient to detect the 
reduction in Hb of ≥25 % in, a population with genotypic 
G6PD deficiency prevalence of 10 %.
Data were double entered in an electronic database 
and analysed using SPSS software version 16 (SPSS Inc, 
Chicago, USA). All the assessments were done by phe-
notypic/genotypic G6PD status and treatment arm. 
Independent sample t test was used to compare abso-
lute and relative mean changes in Hb concentration in 
hemizygous/homozygous and heterozygous patients 
against G6PD wild-type/normal, or phenotypic G6PD 
deficient against normal patients within treatment arms. 
In an additional assessment, phenotypic or genotypic 
(hemizygous/homozygous) G6PD deficient patients 
from both arms were pooled, and their absolute and rel-
ative mean changes in Hb concentration were compared 
against G6PD normal patients. Pre-treatment Hb, para-
sitaemia, age and sex were included in a linear regression 
model to adjust for their effect on relative Hb reduction 
between days 0 and 7. Comparison of proportions was 
performed using Chi square test. Kappa test was used to 
test the agreement between phenotypic and genotypic 
G6PD test results. Data from patients lost to follow-up 
or who withdrew consent were censored at the time of 
exit from study. A p  <  0.05 was defined as statistically 
significant.
Results
A total of 1065 patients was screened for eligibility, 363 
(34.1 %) had a positive P. falciparum blood slide, of whom 
143 were excluded (Fig.  1). The remaining 220 were 
enrolled in the study, 110 each were allocated AL and 
AL + PQ treatment. Baseline characteristics of the study 
groups are presented in Table 1.
G6PD status
PhenotypicG6PD status
Phenotypic G6PD results were available for 217 (98.6 %) 
patients, 33 (15.2  %) were G6PD deficient, of whom 
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21/107 (19.6 %) were males and 12/110 (10.9 %) females. 
The distribution of phenotypic G6PD deficiency was 
19/109 (17.4 %) in the AL arm and 14/108 (12.9 %) in the 
AL + PQ arm, (p = 0.36).
Genotypic G6PD status
G6PD allele frequency distribution is presented in Fig. 2, 
whereas distribution of patients by sex, genotypic G6PD 
status and treatment arm are presented in Table 2. Strati-
fication of patients by sex and genotypic G6PD status did 
not affect distribution of patients within treatment arms.
Phenotypic and genotypic G6PD test agreement
Overall agreement between phenotypic and genotypic 
G6PD test results was poor (Kappa coefficient 0.076, 
p = 0.29). The agreement between the tests for individual 
G6PD genotypes is presented in Table 3.
Hb reduction between days 0 and 7 by phenotypic or 
genotypic G6PD status and treatment arm
Absolute Hb reduction
The absolute mean Hb reduction by phenotypic G6PD 
status is presented in Table 4a. Pooling all 33 phenotypic 
Fig. 1 Trial profile of the study participants
Table 1 Baseline characteristics
a  Mann–Whitney test
b Student t-test
c Chi square test
Characteristic Treatment arm P value
AL (N = 110) AL + PQ (N = 110)
Female sex, n (%) 55 (50) 55 (50)
Age (years), median (range) 10 (1–84) 9 (1–75) 0.392a
Body weight(kg), mean (SD) 34.3 (19.6) 30.7 (17.1) 0.145b
Body temperature(0C), mean (SD) 38.3 (1.3) 38.3 (1.1) 0.977b
Haemoglobin concentration (g/dl), mean (SD) 11.4 (1.6) 11.1 (1.5) 0.097b
Geometric mean asexual parasite density/µl, (range) 8384 (240–389,045) 8327 (240–288,403) 0.982b
Fever (> 37.5 °C) at inclusion, n (%) 80 (72.7) 88 (80.0) 0.204c
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G6PD deficient patients together did not result in any 
statistically significant difference in Hb reduction com-
pared with G6PD normal patients.
The absolute mean Hb reduction by genotypic G6PD 
status is presented in Table  4b. The absolute mean 
Hb reduction among heterozygous and hemizygous/
homozygous patients treated with AL was 1.68  g/dL 
(95 % CI 0.87–2.51), p = 0.048, and 0.35 g/dL (95 % CI 
0.36–1.1), respectively. The corresponding results in 
the AL +  PQ arm were, 1.27  g/dL (95  % CI 0.56–1.99, 
p = 0.09) and 1.48 g/dL (95 % CI 0.59–2.37, p = 0.047), 
respectively. After all 20 hemizygous/homozygous 
patients were pooled and compared with G6PD wild-
type/normal, no statistically significant difference in Hb 
reduction was observed.
A total of 54/101(53.5 %) and 60/105 (57.1 %), p = 0.59, 
patients treated with AL and AL + PQ arms, respectively, 
recovered their Hb by day 28 to or above the initial values 
(Fig. 3). After the phenotypic/genotypic deficient patients 
were pooled, there was no statistically significant differ-
ence in the proportion of patients with Hb recovery by 
day 28 compared with G6PD normal patients.
Relative Hb reduction
The percentage relative mean Hb reductions by pheno-
typic G6PD status are presented in Table 4a. A pooling of 
all phenotypically G6PD deficient patients did not result 
in any statistically significant difference in Hb reduction 
compared with G6PD normal patients.
The mean Hb reduction by genotypic G6PD status 
are presented in Table 4b. The relative mean Hb reduc-
tion in heterozygous patients treated with AL was 14.3 % 
(95 % CI 7.02–21.55, p = 0.045). The mean Hb reduction 
in heterozygous and hemizygous/homozygous patients 
treated with AL  +  PQ did not differ significantly to 
G6PD wild-type/normal patients. The percentage relative 
Hb reduction after adjustment for baseline parasitaemia, 
Hb, age and sex are presented in Table 5. After adjusting 
for the baseline characteristics, the relative Hb reduction 
was non-significant in both heterozygous and hemizy-
gous patients. Pooling hemizygous/homozygous patients 
together did not result in any statistically significant dif-
ference in Hb reduction compared with G6PD wild-type/
normal.
A total of 4/89 (4.5  %) and 1/10 (10.0  %) G6PD wild-
type/normal and heterozygous patients, respectively, 
treated with AL experienced an Hb reduction  ≥25  %. 
The corresponding results in the AL  +  PQ arm were 
1/89 (1.1  %) and 1/12 (8.3  %), respectively. None of the 
hemizygous/homozygous patients in either the AL or 
Fig. 2 G6PD G202A allele frequency distribution. (Male hemizy-
gous = A-; Male wild-type/normal = A or B; Female homozy-
gous = A-A-; Female heterozygous = AA- or BA-; Female wild-type/
normal = AA, BA or BB)
Table 2 Distribution of patients by sex, genotypic G6PD status and treatment arm
Treatment arm Sex
Male Female
Hemizygous Wild‑type/normal Homozygous Heterozygous Wild‑type/normal
AL 10 (18.2 %) 45 (81.8 %) 1 (1.8 %) 10 (18.2 %) 44 (80.0 %)
AL + PQ 5 (9.1 %) 50 (90.9 %) 4 (7.3 %) 12 (21.8 %) 39 (70.9 %)
Total 15 (13.6 %) 95 (86.4 %) 5 (4.5 %) 22 (20.0 %) 83 (75.5 %)
Table 3 Relationship between  phenotypic and  genotypic 
G6PD test results
Genotype results Phenotype results N/N (%)
Male hemizygous Deficient 9/14 (64.3)
Normal 5/14 (35.7)
Male wild-type/normal Deficient 12/93 (12.9)
Normal 81/93 (87.1)
Female homozygous Deficient 0/5 (0)
Normal 5/5 (100)
Female heterozygous Deficient 4/22 (18.2)
Normal 18/22 (81.8)
Female wild-type/normal Deficient 8/83 (9.6)
Normal 75/83 (90.4)
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AL + PQ arm fulfilled the pre-defined haemolytic thresh-
old (Fig. 4). Some 1/19 (5.3 %) and 4/86 (4.7 %) of pheno-
typic G6PD deficient and normal patients, respectively, 
treated with AL had an Hb reduction ≥25  %. However, 
none of the G6PD deficient and 2/107 (1.9  %) normal 
patients in AL + PQ arm had an Hb reduction ≥25 %.
Adverse events
The distribution of AEs across phenotypic and genotypic 
G6PD status by treatment arm is presented in Table 6. AEs 
occurred in 41.8 % (92/220) of patients, 42.7 % (47/110) in 
AL + PQ and 40.9 % (45/110) in AL arm, p = 0.79. Patients 
with haemoglobinuria in AL + PQ arm had significantly 
higher mean pre-treatment parasite density. Most AEs 
were mild (grade 1) and considered unrelated to the study 
drugs. However, six (4.4 %) episodes of acute haemolytic 
anaemia, three in each treatment arm, occurred (Addi-
tional file 1). Despite fulfilling the pre-defined definition of 
acute haemolytic anaemia all were in overall good general 
condition and did not require any medical intervention. 
There was no statistically significant association between 
baseline characteristics and reported AE.
Discussion
The results from this randomized clinical trial supports 
the view that the new WHO recommendation of adding 
a single low-dose of PQ to standard AL regimen was safe 
Table 4 Mean Hb reduction between days 0 and 7 by G6PD 
status and treatment arm
Characteristic Treatment arm
AL AL + PQ
A: Mean absolute and relative Hb reduction by phenotypic G6PD status
Mean absolute Hb reduction (g/dL) (95 % CI)
G6PD normal 0.83 (0.57–1.10) 0.81 (0.59–1.02)
G6PD deficient 0.88 (0.32–1.45) 1.16 (0.67–1.66)
P value 0.87 0.23
Mean relative Hb reduction (%) (95 % CI)
G6PD normal 6.4 (4.29–8.56) 7.2 (5.04–9.35)
G6PD deficient 7.8 (4.23–11.36) 7.9 (4.58–11.18)
P value 0.71 0.16
B: Mean absolute and relative Hb reduction by genotypic G6PD status
Mean absolute Hb reduction (g/dL) (95 % CI)
G6PD wild-type/normal 0.82 (0.56–1.1) 0.74 (0.52–0.95)
G6PD heterozygous 1.68 (0.87–2.51) 1.27 (0.56–1.99)
P value 0.048 0.09
G6PD hemizygous/homozygous 0.35 (−0.36–1.1) 1.48 (0.59–2.37)
P value 0.21 0.047
Mean relative Hb reduction (%) (95 % CI)
G6PD wild-type/normal 6.8 (4.67–8.96) 6.2 (4.25–8.17)
G6PD heterozygous 14.3 (7.02–21.55) 10.9 (5.10–16.87)
P value 0.045 0.09
G6PD hemizygous/homozygous 2.7 (4.22–9.68) 12.6 (6.0–19.25)
P value 0.21 0.059
Fig. 3 Mean absolute change in Hb concentration (g/dl) per treatment arm and genotypic G6PD status. (Normal represents wild-type)
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for the treatment of acute uncomplicated P. falciparum 
malaria in Tanzania regardless of individual G6PD status.
In this study, only G6PD heterozygous patients treated 
with AL had statistically significant percentage relative 
Hb reduction, but none fulfilled the  ≥25  % haemolytic 
threshold. After adjustment for baseline characteristics, 
none of the patient had significant Hb reduction either 
in AL or AL + PQ arm. The reason why a significant Hb 
reduction between enrolment and day 7 occurred in het-
erozygous patients treated with AL alone remains unclear. 
Previous African safety studies have shown that het-
erozygous and hemizygous/homozygous malaria patients 
treated with higher single PQ doses (i.e., 0.4 and 0.75 mg/
kg), in addition to standard ACT, were associated with 
statistically significant reductions in Hb on day 7, but 
without life threatening incidents [21, 22], whereas treat-
ment with a lower single PQ dose, (i.e., 0.1  mg/kg) and 
AL alone did not result in a significant Hb reduction [22]. 
A study in Myanmar also revealed that, treatment with 
0.25 mg/kg single-dose PQ did not result into a significant 
Hb reduction in G6PD deficient individuals [23]. These 
findings suggest that the current WHO recommendation 
of a single 0.25 mg/kg PQ dose is unlikely to result in life-
threatening haemolysis regardless of G6PD status [4]. Of 
note is, however, that other factors including for example 
baseline parasitaemia and pre-existing anaemia have been 
proposed to influence the magnitude of PQ-related hae-
molysis in hemizygous/homozygous [6], which is in line 
with findings from this study.
In this study, more than half of the patients in each 
treatment arm recovered their Hb by day 28 to values 
equal to or higher than baseline, with the lowest Hb lev-
els most often noted between days 2 and 7 after treat-
ment initiation. This is in agreement with findings from 
previous studies in uncomplicated P. falciparum patients 
during follow-up after ACT treatment with or without 
addition of 0.75 mg/kg single PQ dose which showed that 
Hb dropped between days 2 and 7 and then started to 
recover [24–26].
A majority of the episodes of acute haemolysis in this 
study occurred in PCR determined G6PD wild-type/
normal and heterozygous patients. Furthermore, most 
Table 5 Linear regression models of relative change in Hb 
between days 0 and 7
Adjustment was done for baseline Hb, parasite density, age and sex
Treatment arm Variable Coefficient 95 % CI P value
AL Heterozygous −6.61 −13.75 to 0.53 0.124
Hemi/
Homozy-
gous
4.29 −1.87 to 10.45 0.407
AL + PQ Heterozygous −3.97 −8.98 to 1.03 0.095
Hemi/
Homozy-
gous
−6.22 −12.22 to −0.22 0.068
Fig. 4 Mean relative change in Hb concentration (g/dl) per treatment arm between days 0 and 7. (Points show individual relative change, solid line 
segment is the mean while the dotted line indicates a threshold line at 25 %. Normal represents wild-type)
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of the episodes of haemoglobinuria occurred in G6PD 
wild-type/normal patients in AL  +  PQ arm. Analysis 
of the association of pre-treatment characteristics with 
haemoglobinuria showed that, patients with haemoglo-
binuria in AL +  PQ arm had significantly higher mean 
pre-treatment parasitaemia. These findings are in agree-
ment with the observations that haemolysis in P. falci-
parum malaria is a common phenomenon especially in 
individuals with high pre-treatment parasite density [27]. 
Only six patients in total, three per treatment arm, ful-
filled the definition of acute haemolytic anaemia. Inter-
estingly, none were PCR determined G6PD hemizygous/
homozygous, but three were phenotypically G6PD defi-
cient. Importantly, all patients with acute haemolytic 
anaemia were in overall good general medical condition 
and recovered without medical intervention.
The phenotypic test captured 64  % of hemizygous 
males and 18  % of the heterozygous females. None of 
Table 6 Distribution of adverse events by phenotypic or genotypic G6PD status and treatment arm
Adverse event Treatment arm
AL AL + PQ
Normal Deficient Normal Deficient
A: Distribution of adverse events by phenotypic G6PD status
Abdominal pain 6 (10.5 %) 1 (7.1 %) 6 (10.7 %) 1 (11.1 %)
Blurred vision 1 (1.8 %) 0 0 0
Cold sores 2 (3.5 %) 1 (7.1 %) 4 (7.1 %) 0
Diarrhoea 3 (5.3 %) 1 (7.1 %) 2 (3.6 %) 1 (11.1 %)
Dizziness 2 (3.5 %) 0 1 (1.8 %) 0
Fever 21 (36.8 %) 3 (21.4 %) 14 (25.0 %) 2 (22.2 %)
Headache 7 (12.3 %) 1 (7.1 %) 5 (8.9 %) 0
Hb fall ≥ 25 % 5 (8.8 %) 2 (14.3 %) 5 (8.9 %) 0
Acute haemolytic anaemia 1 (1.8 %) 2 (14.3 %) 2 (3.6 %) 1 (11.1 %)
Haemoglobinuria 1 (1.8 %) 2 (14.3 %) 10 (17.9 %) 4 (44.4 %)
Nausea 2 (3.5 %) 0 0 0
Rashes 0 0 1 (1.8 %) 0
Vomiting 5 (8.8 %) 1 (7.1 %) 6 (10.7 %) 0
Weakness 1 (1.8 %) 0 0 0
Total 57 (100 %) 14 (100 %) 56 (100 %) 9 (100 %)
AL AL + PQ
Wild‑type/normal Heterozygous Hemizygous/
homozygous
Wild‑type/normal Heterozygous Hemizygous/
homozygous
B: Distribution of adverse events by genotypic G6PD status
Abdominal pain 7 (11.3 %) 0 0 4 (8.0 %) 4 (44.0 %) 0
Blurred vision 1 (1.6 %) 0 0 0 0 0
Cold sores 3 (4.8 %) 0 0 4 (8.0 %) 0 0
Diarrhoea 2 (3.2 %) 1 (12.5 %) 1 (100 %) 3 (6.0 %) 0 0
Dizziness 1 (1.6 %) 1 (12.5 %) 0 0 1 (10.0 %) 0
Fever 21(33.9 %) 3 (37.5 %) 0 10 (20.0 %) 3 (30.0 %) 3 (50.0 %)
Headache 8 (12.9 %) 0 0 4 (8.0 %) 0 1 (16.7 %)
Hb fall ≥ 25 % 5 (8.1 %) 2 (25.0 %) 0 5 (10.0 %) 0 0
Acute haemolytic 
anaemia
3 (4.8 %) 0 0 2 (4.0 %) 1 (10.0 %) 0
Haemoglobinuria 3 (4.8 %) 0 0 12 (24.0 %) 1 (10.0 %) 1 (16.7 %)
Nausea 1 (1.6 %) 1 (12.5 %) 0 0 0 0
Rashes 0 0 0 1 (2.0 %) 0 0
Vomiting 6 (9.7 %) 0 0 5 (10.0 %) 0 1 (16.7 %)
Weakness 1 (1.6 %) 0 0 0 0 0
Total 62 (100 %) 8 (100 %) 1 (100 %) 50 (100 %) 10 (100 %) 6 (100 %)
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the homozygous females was captured by the test. How-
ever, the phenotypic test performed well in capturing 
wild-type/normal male and female individuals. A study 
in Cambodia showed a rapid test had a sensitivity and 
specificity of 68 and 100 %, respectively, and also it identi-
fied only 40 % of heterozygous females as deficient [28]. 
Conversely, in this study some patients were phenotypi-
cally deficient, but genotypically wild-type/normal. The 
possible explanation for this discrepancy is that, first, in 
this study patients with faint purple colour on the rapid 
tests windows were considered G6PD deficient according 
to the manufacture instructions, however, in a study con-
ducted in Cambodia the faint colour was considered nor-
mal [28], thus if in this study the assessment would have 
been done as in Cambodia the discordance could have 
been reduced. Second, the genotypic test used only tar-
geted the two most common African G6PD variants, i.e. 
A376G and G202A, therefore, leaving out the rare vari-
ants which were probably detected by the phenotypic test. 
Conversely, most heterozygous patients were missed by 
the phenotypic test probably because heterozygous indi-
viduals have a mixture of cells with deficient and normal 
G6PD activity, and the activity of the later may therefore 
mask the deficiency [3, 29]. However, it is not well under-
stood why the phenotypic test missed some hemizygous 
and all the homozygous patients. In anaemic patients, 
presence of young erythrocytes masks the deficiency and 
may result into a false negative results by phenotypic tests 
[3]. However, in this study hemizygous and homozygous 
but phenotypically normal patients had similar base-
line Hb concentration as hemizygous and phenotypically 
deficient patients. The herein observed and previously 
reported discrepancies between G6PD genotype and phe-
notype results underline the importance of standardiza-
tion of PCR genotyping in these kinds of studies, but also 
calls for the development of improved phenotypic G6PD 
point-of-care tests. However, missing of these deficient 
individuals by the rapid test would pose no safety risk in 
the context of P. falciparum elimination as the findings 
have shown that the observed Hb drop after treatment 
with this single low-dose PQ was of no clinical signifi-
cance. The PQ single low-dose is also recommended to be 
used without testing for G6PD status [6].
One of the strength of this study is that patients were 
included regardless of G6PD status and randomly allo-
cated to treatment with or without a single low-dose of 
PQ in addition to standard AL regimen. Furthermore, 
this is one of the few studies to look at the 0.25  mg/kg 
dose in Africa and contributes to an evidence base that 
was otherwise lacking. Limitations of the study include: 
that some young children had difficulties to remember 
and explain potential adverse events. Only the two most 
common African G6PD deficient A376G and G202A 
variants were genotyped, hence potentially missing the 
rare variants which could have explained the discrepan-
cies observed between phenotypic and genotypic tests. 
No further assessment was done to confirm whether the 
observed Hb drop was due to other factors than hae-
molysis. Only patients with Hb  ≥8  g/dL were included 
in the study, hence it is difficult to predict how patients 
with lower Hb would respond to PQ treatment particu-
larly at the community level where the impact of PQ use 
is of more significant. However, asymptomatic parasites 
carriers are the target at the community level, and usually 
this group has low parasitaemia and Hb level that does 
not pose a risk with PQ use, particularly with this single 
low-dose as recommended by WHO.
Conclusion
The findings from this study support the new WHO rec-
ommendation that the addition of a single low-dose of 
PQ (0.25 mg/kg) to standard AL is safe for the treatment 
of uncomplicated acute P. falciparum malaria in Tanzania 
regardless of individual G6PD status.
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